Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure

Osimertinib is a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. Pneumonitis is a severe adverse event (AE) related to osimertinib treatment which appears to be more frequent when associated with concurrent or previous anti-PD(L)...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ecancermedicalscience
Main Authors: Harada, Guilherme, Santini, Fernando Costa, Canedo, Felipe Sales Nogueira Amorim, de Carvalho Oliveira, Leandro Jonata, Zuppani, Henrique Bortot, De Castro, Gilberto
Formato: Artigo
Idioma:Inglês
Publicado: Cancer Intelligence 2019
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6834382/
https://ncbi.nlm.nih.gov/pubmed/31921341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2019.970
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares